drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified autologous T cells; CAR T-cell therapy)
drug_description
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy; patient T cells are gene-modified to express a CD19-targeted CAR that, upon antigen engagement, activates T-cell cytotoxicity to eliminate CD19-positive B-cell malignancies and induce B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene‑modified to express an anti‑CD19 chimeric antigen receptor; binding to CD19 on B cells activates CAR signaling and T‑cell cytotoxicity, leading to elimination of CD19‑positive malignant B cells and on‑target B‑cell aplasia.
drug_name
AUTO1 (obecabtagene autoleucel; obe-cel)
nct_id_drug_ref
NCT06173518